EGFR and non-small cell lung carcinoma: Notably, encouraging results of a randomized phase II trial testing cabozantinib, erlotinib or the combination in patients with EGFR wild-type NSCLC were presented during ASCO Annual Meeting 2015.[32] Cabozantinib, co-targeting angiogenesis and MET signaling plus erlotinib showed statistically significant improvement in both OS and PFS compared with erlotinib alone.